HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Bullous pemphigoid — Clinical Guidelines

Overview

Bullous pemphigoid (BP) is a common autoimmune subepidermal blistering disease primarily affecting elderly individuals, characterized by intense itching and blister formation due to autoantibodies targeting basement membrane proteins, particularly BP180 and BP230 6.

Diagnosis

Key Diagnostic Criteria: Presence of subepidermal blisters, linear deposition of IgG and C3 at the dermoepidermal junction on direct immunofluorescence 7.

Recommended Tests: Direct and indirect immunofluorescence microscopy, histopathology with immunohistochemistry for C3d, C4d, and IgG 7.

Immunohistochemistry: Useful when frozen tissue is unavailable; detects C3d, C4d, and IgG deposition 7.

Management

First-Line Treatment: Very potent topical corticosteroids (e.g., clobetasol propionate) as monotherapy or adjunctive therapy 12.

Adjunctive Therapies: Systemic corticosteroids for severe cases, immunosuppressants like azathioprine or mycophenolate mofetil for refractory disease 6.

Specific Drug Classes: Consider immune checkpoint inhibitor-associated BP with careful monitoring and potential immunosuppressive therapy 2 3 9.

Special Populations

Elderly: BP predominantly affects older adults; management focuses on minimizing systemic steroid side effects 6.

Comorbidities: Increased risk associated with neurological disorders; comorbidities should guide treatment choices 11.

Pediatrics: Rare cases reported; topical steroids effective in infants 10.

Key Recommendations

Use very potent topical corticosteroids as first-line therapy for bullous pemphigoid 12 (Evidence: Strong).

Consider systemic corticosteroids or immunosuppressants for severe or refractory cases 6 (Evidence: Moderate).

Monitor closely for immune checkpoint inhibitor-associated bullous pemphigoid in patients receiving ICIs, with potential use of immunosuppressive therapy 2 3 9 (Evidence: Moderate).

Evaluate comorbidities, particularly neurological disorders, to tailor management strategies 11 (Evidence: Moderate).

In pediatric cases, topical corticosteroids are effective and should be considered 10 (Evidence: Weak).

References

1 Swiderski M, Figueredo G, Vinogradova Y, Knaggs RD, Harman KE, Harwood RH et al.. Determining the most frequent combinations of drugs prescribed prior to bullous pemphigoid diagnosis using association rule mining: a UK population-based case-control study. Clinical and experimental dermatology 2025. link 2 Wang Y, Yang LY, Zuo YG. Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 2025. link 3 Tan H, Chen X, Chen Y, Ou X, Yang T, Yan X. Immune checkpoint inhibitor-associated bullous pemphigoid: A retrospective and real-world study based on the United States Food and Drug Administration adverse event reporting system. The Journal of dermatology 2025. link 4 Mahesh R, Das K A, Thomas C, Kotakonda SR, Maheshwari K, Undela K. Identifying potential drug triggers for bullous pemphigoid: a disproportionality analysis of the FDA adverse event reporting system and systematic review of case reports. Cutaneous and ocular toxicology 2025. link 5 Granieri G, Oranges T, Morganti R, Janowska A, Romanelli M, Manni E et al.. Ultra-high frequency ultrasound detection of the dermo-epidermal junction: Its potential role in dermatology. Experimental dermatology 2022. link 6 Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R et al.. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology : JEADV 2022. link 7 Oh H, Kim CH, Lee YJ. Bullous pemphigoid diagnosis: the role of routine formalin-fixed paraffin-embedded skin tissue immunochemistry. Scientific reports 2022. link 8 Jedlowski PM, Jedlowski MF, Fazel MT. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020. American journal of clinical dermatology 2021. link 9 Sadik CD, Langan EA, Gutzmer R, Fleischer MI, Loquai C, Reinhardt L et al.. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers. Frontiers in immunology 2020. link 10 Thabouillot O, Le Coz J, Roche NC. Bullous Pemphigoid in an Infant: A Case Report. Prehospital and disaster medicine 2018. link 11 Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, Bartkiewicz P, Dmochowski M. Bullous pemphigoid and neurodegenerative diseases: a study in a setting of a Central European university dermatology department. Aging clinical and experimental research 2016. link 12 Meijer JM, Jonkman MF, Wojnarowska F, Wiliams HC, Kirtschig G. Current practice in treatment approach for bullous pemphigoid: comparison between national surveys from the Netherlands and the UK. Clinical and experimental dermatology 2016. link 13 Försti AK, Jokelainen J, Timonen M, Tasanen K. Risk of Death in Bullous Pemphigoid: A Retrospective Database Study in Finland. Acta dermato-venereologica 2016. link 14 Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T et al.. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. Journal of the American Academy of Dermatology 2012. link 15 Joly P. Incidence of bullous pemphigoid and pemphigus vulgaris. BMJ (Clinical research ed.) 2008. link 16 Zebrowska A, Sysa-Jedrzejowska A, Wagrowska-Danilewicz M, Joss-Wichman E, Erkiert-Polguj A, Waszczykowska E. Expression of selected integrins and selectins in bullous pemphigoid. Mediators of inflammation 2007. link 17 Jackson R. Dühring on dermatitis herpetiformis. Journal of cutaneous medicine and surgery 1999. link 18 Zone JJ, Taylor TB, Kadunce DP, Chorzelski TP, Schachner LA, Huff JC et al.. IgA antibodies in chronic bullous disease of childhood react with 97 kDa basement membrane zone protein. The Journal of investigative dermatology 1996. link 19 de Jong MC, van der Meer JB, de Nijs JA, van der Putte SC. Concomitant immunohistochemical characteristics of pemphigoid and dermatitis herpetiformis in a patient with atypical bullous dermatosis. Acta dermato-venereologica 1983. link

Bullous pemphigoid